GLPwatch

Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.

Endocrinol Metab Clin North Am · 2025

Last updated 2026-05-28

Seven FDA-approved medications are available for obesity management, including liraglutide (3.0 mg), semaglutide (2.4 mg), and tirzepatide. These drugs are intended for long-term use alongside diet, exercise, and behavioral changes. The article reviews their approval data, how they work, dosing, side effects, and other key details.

AI summary of the abstract below.

JournalEndocrinol Metab Clin North Am, 2025
Citations5
Relative citation ratio1.78
Molecules
Conditions studied Obesity

Abstract

Successful treatment of obesity requires a multidisciplinary approach including dietary strategy, physical activity, and behavioral modification. The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication.

Verbatim abstract via PubMed 39919879 ↗